Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS)

Atherosclerosis

Volumn 144, Issue 2, 1999, Pages 409-417

  Nishimura, Shigeyuki ^a   Sekiguchi, Morie ^b   Kano, Tatsuji ^c   Ishiwata, Sugao ^d   Nagasaki, Fumihiko ^e   Nishide, Toshio ^e   Okimoto, Takao ^f   Kutsumi, Yasunori ^g   Kuwabara, Yoichi ^h   Takatsu, Fumimaro ⁱ   Nishikawa, Hideo ^j   Daida, Hiroyuki ^k   Yamaguchi, Hiroshi ^k  

^a YOKOHAMA ROSAI HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e Yaizu Municipal Hospital   (Japan)

^f Tokyo Kita Shakai Hoken Hospital   (Japan)

^g UNIVERSITY OF FUKUI   (Japan)

^h CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ Division of Cardiology   (Japan)

^j ISE RED CROSS HOSPITAL   (Japan)

^k JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Coronary artery disease; Heterozygous familial hypercholesterolemia; LDL apheresis; Regression of coronary lesions

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; COLESTYRAMINE; LOW DENSITY LIPOPROTEIN; NITRATE; PRAVASTATIN; PROBUCOL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; APHERESIS; ARTICLE; BLOOD VESSEL DIAMETER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; JAPAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR LESION;

ADULT; AGED; ANTILIPEMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DIET, FAT-RESTRICTED; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033013792     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00328-1     Document Type: Article

References (30)

1. Thompson G.R., Lowenthal R., Myant N.B. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet. 1:1975;1208-1211.
2. Mabuchi H, Koizumi J, Shimizu M, Takeda R and the Hokuriku FH-CHD Study Group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225-232.
3. Mabuchi H., Michishita M., Takeda M. et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 68:1987;19-25.
4. Rubba P., Iannuzzi A., Postiglione A. et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation. 81:1990;610-616.
5. Berger G.M., Firth J.C., Jacobs P., Wood L., Marais A.D., Horak A. Three different schedules of low-density lipoprotein apheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia. Am J Med. 88:1990;94-100.
6. Gordon BR, Kelsey SF, Biheimer DW, Brown DC, Dau PC, Gotto AMJ, Illingworth DR, Jones PH, Leitman SF, Prihoda JS, Stein EA, Stern TN, Zavoral JH, Zwiener RJ for the Liposorber Study Group. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1992;70:1010-1016.
7. Brensike J.F., Levy R.I., Epstein S.E. et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary intervention study. Circulation. 69:1984;313-324.
8. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc. 264:1990;3007-3012.
9. Brown G., Albers J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatric V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med. 323:1990;1289-1298.
10. Watts G.F., Lewis B., Brunt J.N.H., Lewis E.S., Coltart D.J., Smith L.D.R., Mann J.I., Swan A.V. Effects on coronary artery disease of lipids-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
11. Blankenhorn D.H., Azen S.P., Kramsch D.M. et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med. 119:1993;969-976.
12. Waters D., Higginson L., Gladstone P. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968.
13. Haskell W.L., Alderman E.L., Fair J.M. et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 89:1994;975-990.
14. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
15. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, Mcgovern ME, for the PLAC I Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-1139.
16. Jukema JW, Bruschke AVG, Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, Rappard FM, Lie KI, on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1959;91:2528-2540.
17. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito T, Teramoto T, Yasugi T, Yamamoto A, Goto Y for the LARS investigators. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
18. Kitabatake A, Sato H, Hori M, Kamada T, Kubori S, Hoki N, Minamino T, Yamada M, Kato T, for the Osaka LDL-Apheresis Multicenter Trial Group. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. Clin Ther 1994;16:416-428.
19. Schuff Werner P., Gohlke H. et al. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary artery disease. Eur J Clin Invest. 24:1994;724-732.
20. Thompson G.R., Maher V.M.G., Matthews S., Kitano Y., Neuwirth C., Shortt M.B., Davies G., Rees A., Mir A., Prescott R.J., Feyter P., Henderson A. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816.
21. Kroon A.A., Aengevaeren W.R.M., Werf T.V.D., Uijen G.J.H., Reiber J.H.C., Bruschke A.V.G., Stalenhoef A.F.H. LDL-apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835.
22. Austen W.G., Edwards J.E., Frye R.L. et al. AHA Committee Report. A reporting system on patients evaluated for coronary artery disease. Circulation. 51:1975;5-38.
23. Reiber J.H.C., Serruys P.W., Kooijman C.J. et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer assisted quantification of coronary cineangiograms. Circulation. 71:1985;280-288.
24. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
25. Tresure C.B., Klein L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl J Med. 332:1995;481-487.
26. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selqyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med. 332:1995;488-493.
27. Kojima S., Harada-Shiba M., Toyota Y., Yamamoto A. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs. 15:1992;185-190.
28. Mabuchi H., Koizumi J., Shimizu M. et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol. 82:1998;1495-1498.
29. Yamamoto A., Hara H., Takaichi S., Wakasugi J., Tomilawa M. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol. 62:1988;31B-36B.
30. Komura T., Takahara K., Sugano A., Fujinishi H., Tasaki Y., Nakashima Y., Kuroiwa A. Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol. Eur J Drug Metab Pharmacokinet. 22:1997;201-206.